FOS样抗原1在头颈鳞癌中的表达及临床意义

doi:10.3969/j.issn.1009-976X.2020.03.012

岭南现代临床外科 ›› 2020, Vol. 20 ›› Issue (03): 319-323.DOI: 10.3969/j.issn.1009-976X.2020.03.012

FOS样抗原1在头颈鳞癌中的表达及临床意义

高晓琳¹, 修霞², 邱萍萍^3,*, 张杜合一⁴, 谢舒乐⁴, 林钊宇⁴

1.广州市海珠区口腔医院,广东广州 510220;
2.山东省青岛市黄岛区中心医院,山东青岛 266555;
3. 中山大学孙逸仙纪念医院麻醉科,广东广州 510120;
4.中山大学孙逸仙纪念医院口腔科,广东广州 510120

通讯作者: *邱萍萍,Email：qpp2020@163.com
基金资助:
国家自然科学基金青年项目（81602379, 81903045）

The expression of FOS-like antigen 1 in head and neck squamous cell carcinoma and its clinical significance

GAO Xiao-lin¹, XIU Xia², QIU Ping-ping³, ZHANG DU-he-yi⁴, XIE Shu-le⁴, LIN Zhao-yu⁴

1. Haizhu District Stomatological Hospital, Guangzhou 510220, China;
2. Huangdao District Central Hospital, Department of Stomatology, Qingdao 266555, China;
3. Sun Yet-san Memorial Hospital, Department of Anesthesiology, Guangzhou 510120, China;
4. Sun Yet-san Memorial Hospital,Oral and Maxillofacial Surgery, Guangzhou 510120, China

Received:2020-01-19 Online:2020-06-20 Published:2020-06-20
Contact: QIU Ping-ping, qpp2020@163.com

摘要/Abstract

摘要： 目的探讨FOS样抗原1（FOSL1）蛋白在头颈鳞癌中的表达及其与临床病理特点及患者预后的关系。方法使用UALCAN数据库预测FOSL1在头颈鳞癌（HNSC）中的表达情况,收集98例头颈鳞癌患者,采用免疫组化法检测头颈鳞癌及其癌旁正常组织中FOSL1蛋白的表达,并分析其表达与临床特征的关系。结果 UALCAN数据库及免疫组化结果均显示FOSL1蛋白在头颈鳞癌中的相对表达量明显高于癌旁正常组织（P<0.05）;FOSL1的表达与头颈鳞癌的大小、淋巴结转移、病理分级及HPV状态密切相关（P<0.05）。Kaplan-Meier分析显示FOSL1高表达组HNSC患者总积生存率明显低于低表达组HNSC患者（P< 0.05）。结论 FOSL1蛋白参与头颈鳞癌的发生发展,FOSL1的表达水平有助于头颈鳞癌恶性程度的评价及预后的判断。

关键词: 预后, FOSL1, 头颈鳞癌, 免疫组化

Abstract: Objective To detect the expression of FOS-like antigen 1 （FOSL1） in head and neck squamous cell carcinoma （HNSC） and to investigate the correlation between its expression and the clinical data or prognosis of HNSC patients. Methods The expression of FOSL1 in 98 HNSC patients and the adjacent normal tissues were predicted by UALCAN microarray database. The expression of FOSL1 in head and neck squamous cell carcinoma tissues and normal tissues was further detected by immunohistochemistry （IHC）. The relationship between the FOSL1 expression and clinical characteristics was analyzed bytest, and Kaplan-Meier methods were used to analysis the correlation between FOSL1 protein and HNSC patients' survival. Results UALCAN database and IHC assays showed that the expression of FOSL1 protein in HNSC was significantly higher than that in normal tissues （P<0.05）. The expression of FOSL1 protein was closely correlated with tumor size, lymph node metastasis, pathological grading and HPV status （P<0.05）. Survival analysis showed that the survival rate of FOSL1 high expression group was significantly lower than that of FOSL1 low expression group （P<0.05）. Conclusion FOSL1 is involved in the development and progression of HNSC, and may be useful in evaluating the prognosis.

Key words: prognosis, head and neck squamous cell carcinoma, immunohistochemistry, FOSL1

中图分类号:

R739.9

高晓琳, 修霞, 邱萍萍, 张杜合一, 谢舒乐, 林钊宇. FOS样抗原1在头颈鳞癌中的表达及临床意义[J]. 岭南现代临床外科, 2020, 20(03): 319-323.

GAO Xiao-lin, XIU Xia, QIU Ping-ping, ZHANG DU-he-yi, XIE Shu-le, LIN Zhao-yu. The expression of FOS-like antigen 1 in head and neck squamous cell carcinoma and its clinical significance[J]. Lingnan Modern Clinics in Surgery, 2020, 20(03): 319-323.

参考文献

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34.
[2] Xie SL, Fan S, Zhang SY, et al.SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway[J]. Int J Cancer, 2018, 142(6):1252-1265.
[3] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[4] Elangovan IM, Vaz M, Tamatam CR, et al.FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation[J]. Am J Respir Cell Mol Biol, 2018,58(5):625-635.
[5] Han Y, Zhao X, Sun Y, et al.Effects of FOSL1 silencing on osteosarcoma cell proliferation, invasion and migration through the ERK/AP-1 signaling pathway[J]. J Cell Physiol, 2019,234(4):3598-3612.
[6] Cai B, Wu J, Yu X, et al.FOSL1 inhibits type Ⅰ interferon responses to malaria and viral infections by blocking TBK1 and TRAF3/TRIF interactions[J]. mBio, 2017,8(1): e02161-16.
[7] Shaulian E.AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise?[J] Cell Signal, 2010, 22(6):894-899.
[8] Jiang X, Xie H, Dou Y, et al.Expression and function of FOSL1 protein in tumors[J]. Mol Biol Rep, 2020,47(1):737-752.
[9] Young MR, Colburn NH.Fra-1 a target for cancer prevention or intervention[J]. Gene, 2006,379:1-11.
[10] Kawabata K, Murakami A, Ohigashi H.Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells[J]. BiosciBiotechnolBiochem, 2005, 69(2):307-314.
[11] Galvagni F, Orlandini M, Oliviero S.Role of the AP-1 transcription factor FOSL1 in endothelial cells adhesion and migration[J]. Cell AdhMigr, 2013,7(5):408-411.
[12] Letson C, Padron E.Non-canonical transcriptional consequences of BET inhibition in cancer[J]. Pharmacol Res, 2019,150:104508.
[13] Vallejo A, Perurena N, Guruceaga E, et al.An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer[J]. Nat Commun, 2017,8:14294.
[14] Luo YZ, He P, Qiu MX.FOSL1 enhances growth and metastasis of human prostate cancer cells through epithelial mesenchymal transition pathway[J]. Eur Rev Med Pharmacol Sci, 2018,22(24):8609-8615.
[15] Chandrashekar DS, Bashel B, Balasubramanya SAH, et al.UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8):649-658.

FOS样抗原1在头颈鳞癌中的表达及临床意义

The expression of FOS-like antigen 1 in head and neck squamous cell carcinoma and its clinical significance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	何冲, 周姝睿, 李雅晴, 陈少杰, 练国达, 陈尚祥, 黄开红. 胰腺癌预后相关铁死亡基因筛选及预后预测模型构建[J]. 岭南现代临床外科, 2022, 22(1): 14-23.
[2]	刘伟. 恶性脑胶质瘤单放和放化疗临床疗效5年随诊分析[J]. 岭南现代临床外科, 2022, 22(1): 89-93.
[3]	赵昭, 阎晓玲. ESM-1在复发性垂体腺瘤中的表达及意义[J]. 岭南现代临床外科, 2022, 22(1): 94-97.
[4]	胡明超, 朱宝松. NDC1基因在结肠癌中诊断及预后价值的生物信息学分析：一项基于TCGA数据库的研究[J]. 岭南现代临床外科, 2021, 21(06): 598-602.
[5]	宋燕州, 康志龙, 苏一男, 张毅明, 赵新, 李志伟, 李伟. NEK7在原发性肝细胞肝癌患者中表达及其临床意义[J]. 岭南现代临床外科, 2021, 21(06): 608-613.
[6]	王道笃, 赵其炯, 周志标, 何永越. 基于铁死亡相关基因构建肝细胞癌的预后模型[J]. 岭南现代临床外科, 2021, 21(04): 419-424.
[7]	王庆斌, 商昌珍, 陈亚进. 肝癌切除术后预后预测的研究进展[J]. 岭南现代临床外科, 2021, 21(04): 471-476.
[8]	朱钊雯, 贾卫娟, 刘洁琼. Luminal型乳腺癌胞膜蛋白相关预后模型的构建与验证[J]. 岭南现代临床外科, 2021, 21(03): 281-286.
[9]	曾兵, 李锦宏, 蔡灿锋, 辛海洋, 曾军. ITGAV在结直肠癌中的表达及临床意义[J]. 岭南现代临床外科, 2021, 21(03): 309-312.
[10]	伍隽华, 陈云扬, 张鑫, 余杰雄, 崔恩铭, 张慧玲. 肝癌患者中RNF24的表达及临床价值[J]. 岭南现代临床外科, 2021, 21(02): 165-170.
[11]	张果, 张瑞, 陈进宏. 结直肠癌肝转移预后评分系统的现状及临床应用[J]. 岭南现代临床外科, 2021, 21(01): 11-16.
[12]	霍励耘, 魏英城, 谭文亮, 商昌珍, 陈亚进. SMC基因家族在肝癌中的表达及其预测肝癌预后的临床意义[J]. 岭南现代临床外科, 2021, 21(01): 24-28.
[13]	黄贻培, 罗伟鑫, 许磊波. 转录因子YY1在肝细胞癌中的表达和功能研究[J]. 岭南现代临床外科, 2021, 21(01): 44-52.
[14]	张华耀, 许水英, 林思园, 张利华, 张致远, 梁宝珍, 刘颖升, 李想娣. 年轻乳腺癌的临床病理特点及预后因素分析：基于SEER数据库的回顾性研究[J]. 岭南现代临床外科, 2021, 21(01): 91-95.
[15]	黄勇平, 唐德钧, 刘冬, 张环, 唐光华, 都敏, 杨小兰. SUB1在肝癌患者中的预后价值[J]. 岭南现代临床外科, 2020, 20(04): 425-430.